Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R289 in Lower-risk Myelodysplastic Syndromes (LR MDS)
NCT05308264Phase 2Recruiting
- Sponsor
- Rigel Pharmaceuticals, Inc.
- Start
- Sep 2022
- Primary completion
- Aug 2026
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of R289 in myelodysplastic syndrome (MDS), sponsored by Rigel Pharmaceuticals, Inc.. Started Sep 2022; status: recruiting.
02
Drugs
R289
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT05308264.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05308264.